CVC Catalyst III has agreed to acquire a majority stake in WillowWood, a long-established prosthetic technology company known for its prosthetic liners, feet, knees, suspension systems and custom solutions.
The transaction will see CVC acquire the majority position from Blue Sea Capital, the Arbogast family and WillowWood management. Blue Sea Capital, the Arbogast family and management will reinvest substantially in the company, while Mahesh Mansukhani and Daniel Rubin will continue as co-CEOs.
For India’s prosthetics and orthotics sector, the deal is important because it highlights the increasing global investor interest in prosthetic technology, limb care, socket interface systems and international expansion in O&P.
A Major Global Prosthetics Brand Enters a New Investment Phase
WillowWood was founded in 1907 in Mount Sterling, Ohio, by William E. Arbogast, a bilateral amputee. Over more than a century, the company has grown into one of the best-known prosthetic product manufacturers in the United States and selected international markets.
The company is particularly recognised for its prosthetic liner technology, including the ALPHA liner range. Prosthetic liners are a critical part of the socket interface because they directly affect comfort, suspension, skin protection and day-to-day prosthetic use.
WillowWood also offers prosthetic feet, prosthetic knees, suspension systems and custom solutions. According to the company’s official announcement, it now offers around 1,000 SKUs and has developed custom liner capabilities for more complex patient needs.
Why This Matters for Bharat CPO Readers
India has one of the world’s largest populations of people who require prosthetic and orthotic care. Demand is driven by road traffic accidents, diabetes-related amputations, vascular disease, congenital limb differences, trauma, cancer-related amputations and workplace injuries.
In this context, investment in global prosthetic manufacturers matters because it can influence the future availability, affordability and development of prosthetic technologies used by clinicians and patients in India.
The official WillowWood announcement states that the new partnership with CVC is expected to support research and development, new product innovation, mergers and acquisitions, international growth and expansion of WillowWood’s commercial footprint.
Although the announcement specifically highlights a direct commercial footprint in Europe, broader international expansion by a major prosthetic manufacturer may eventually have implications for India and other high-growth O&P markets.
Prosthetic Liners and Socket Comfort Remain Critical in India
For Indian prosthetists, one of the most relevant aspects of WillowWood’s portfolio is its focus on liners and the socket interface.
In India, amputees often face hot and humid climates, long daily wear times, high mobility demands, limited follow-up access and cost pressure around replacement components. Socket comfort, skin health, suspension and liner durability are therefore central to successful prosthetic rehabilitation.
Advanced liner technologies may offer better comfort and skin protection, but access and affordability remain major issues in many parts of India. This is especially true for patients outside large metropolitan centres or those dependent on charitable, government or NGO-supported prosthetic services.
For India’s O&P sector, the important question is not only whether more advanced prosthetic products are developed globally, but whether they can be made available through appropriate pricing, training, distribution and clinical support models.
Private Equity Interest in O&P Is Growing
The WillowWood transaction also reflects a wider trend: prosthetics and orthotics is increasingly being viewed as a specialist healthcare technology segment with long-term growth potential.
For investors, O&P combines several attractive factors: ageing populations, increasing diabetes and vascular disease, greater demand for mobility solutions, technological innovation and growing awareness of rehabilitation. For clinicians, however, investment must ultimately translate into better products, improved access, training and patient outcomes.
Private equity investment can support product development, manufacturing scale, international distribution and acquisitions. At the same time, the O&P profession must continue to watch how consolidation affects pricing, component availability, distributor relationships and clinical choice.
For India, this is particularly important because prosthetic care spans a wide economic range: from high-end private fittings in major cities to low-cost and charitable limb services across district and rural settings.
Potential Relevance for Indian Distributors and Clinics
The deal may also be relevant for Indian distributors, prosthetic workshops, rehabilitation hospitals and private O&P clinics.
If WillowWood expands internationally, Indian O&P businesses may watch for future changes in regional distribution, training availability, product access and partnership opportunities. For manufacturers and suppliers already active in India, the transaction is another sign that global O&P companies may become more commercially focused on growth markets.
India’s prosthetics sector is also increasingly influenced by digital workflows, 3D printing, advanced materials, custom liners, modular components and outcome-focused rehabilitation. Global investment in companies such as WillowWood may accelerate product development in these areas.
However, for the Indian market, success will depend on how technologies are adapted to local clinical realities, including affordability, after-sales support, practitioner training, procurement systems and service access beyond tier-one cities.
Continuity in Leadership
WillowWood’s existing co-CEOs, Mahesh Mansukhani and Daniel Rubin, will continue to lead the company. Ryan Arbogast, a fourth-generation member of the founding family, will also continue to support the company’s mission.
This continuity may be reassuring for clinicians and partners because it suggests the transaction is not simply a change of ownership, but an attempt to scale an established prosthetic technology platform.
WillowWood says it has launched 18 new products since 2021 and continues to work with academic institutions on product and clinical research. This focus on innovation will be closely watched by prosthetists and distributors looking for future developments in liners, limb health, prosthetic feet, knees and custom solutions.
Transaction Expected to Close in Q3 2026
The financial terms of the deal were not disclosed. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals.
For India’s O&P community, the acquisition is worth following because it shows how prosthetic technology is becoming an increasingly strategic area of global healthcare investment. As international manufacturers scale, Indian clinicians, distributors and rehabilitation providers will need to assess how these developments can support better amputee care while remaining practical and affordable for the Indian market.
- WillowWood official announcement
- WillowWood
- WillowWood liners
- WillowWood prosthetic feet
- WillowWood prosthetic knees
- CVC
- Blue Sea Capital
- AOPA